MONOTERAPIA CON VIGABATRIN IN SOGGETTI CON EPILESSIA PARZIALE DI NUOVA DIAGNOSI: RISULTATI PRELIMINARI DI UNO STUDIO COLLABORATIVO APERTO

M. R. De Feo; O. Mecarelli; M. G. Marciani; S. Striano; A. Ortenzi; G. Cerone; P. D'Alessandro; M. Onofri

MONOTERAPIA CON VIGABATRIN IN SOGGETTI CON EPILESSIA PARZIALE DI NUOVA DIAGNOSI: RISULTATI PRELIMINARI DI UNO STUDIO COLLABORATIVO APERTO

Translated title of the contribution: Vigabatrin monotherapy in partial epilepsy: Preliminary results of a open collaborative study

M. R. De Feo, O. Mecarelli, M. G. Marciani, S. Striano, A. Ortenzi, G. Cerone, P. D'Alessandro, M. Onofri

Fondazione Santa Lucia

Research output: Contribution to journal › Article › peer-review

Abstract

In 48 new diagnosed epileptic patients, affected by partial simple or complex seizures with or without secondary generalization, GVG was administered as unique drug at a mean dose of 29 mg/kg/day. Minimum follow-up was 3 months, maximum 12 months. In about 80% of the patients a disappearance or a reduction ≥50% of the seizure frequency was obtained, without significant differences between cryptogenic and symptomatic etiology, thoughout the whole period of observation. Side effects, mainly body weight increment, were usually mild and transitory.

Translated title of the contribution	Vigabatrin monotherapy in partial epilepsy: Preliminary results of a open collaborative study
Original language	Italian
Pages (from-to)	81-82
Number of pages	2
Journal	Bollettino - Lega Italiana contro l'Epilessia
Issue number	86-87
Publication status	Published - 1994

ASJC Scopus subject areas

Clinical Neurology

Cite this

@article{3ec259339a894f19a08422d23521e9db,

title = "MONOTERAPIA CON VIGABATRIN IN SOGGETTI CON EPILESSIA PARZIALE DI NUOVA DIAGNOSI: RISULTATI PRELIMINARI DI UNO STUDIO COLLABORATIVO APERTO",

abstract = "In 48 new diagnosed epileptic patients, affected by partial simple or complex seizures with or without secondary generalization, GVG was administered as unique drug at a mean dose of 29 mg/kg/day. Minimum follow-up was 3 months, maximum 12 months. In about 80% of the patients a disappearance or a reduction ≥50% of the seizure frequency was obtained, without significant differences between cryptogenic and symptomatic etiology, thoughout the whole period of observation. Side effects, mainly body weight increment, were usually mild and transitory.",

author = "{De Feo}, {M. R.} and O. Mecarelli and Marciani, {M. G.} and S. Striano and A. Ortenzi and G. Cerone and P. D'Alessandro and M. Onofri",

year = "1994",

language = "Italian",

pages = "81--82",

journal = "Bollettino - Lega Italiana contro l'Epilessia",

issn = "0394-560X",

publisher = "Lega Italiana contro l'Epilessia",

number = "86-87",

}

TY - JOUR

T1 - MONOTERAPIA CON VIGABATRIN IN SOGGETTI CON EPILESSIA PARZIALE DI NUOVA DIAGNOSI

T2 - RISULTATI PRELIMINARI DI UNO STUDIO COLLABORATIVO APERTO

AU - De Feo, M. R.

AU - Mecarelli, O.

AU - Marciani, M. G.

AU - Striano, S.

AU - Ortenzi, A.

AU - Cerone, G.

AU - D'Alessandro, P.

AU - Onofri, M.

PY - 1994

Y1 - 1994

N2 - In 48 new diagnosed epileptic patients, affected by partial simple or complex seizures with or without secondary generalization, GVG was administered as unique drug at a mean dose of 29 mg/kg/day. Minimum follow-up was 3 months, maximum 12 months. In about 80% of the patients a disappearance or a reduction ≥50% of the seizure frequency was obtained, without significant differences between cryptogenic and symptomatic etiology, thoughout the whole period of observation. Side effects, mainly body weight increment, were usually mild and transitory.

AB - In 48 new diagnosed epileptic patients, affected by partial simple or complex seizures with or without secondary generalization, GVG was administered as unique drug at a mean dose of 29 mg/kg/day. Minimum follow-up was 3 months, maximum 12 months. In about 80% of the patients a disappearance or a reduction ≥50% of the seizure frequency was obtained, without significant differences between cryptogenic and symptomatic etiology, thoughout the whole period of observation. Side effects, mainly body weight increment, were usually mild and transitory.

UR - http://www.scopus.com/inward/record.url?scp=0028674569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028674569&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0028674569

SP - 81

EP - 82

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 86-87

ER -

MONOTERAPIA CON VIGABATRIN IN SOGGETTI CON EPILESSIA PARZIALE DI NUOVA DIAGNOSI: RISULTATI PRELIMINARI DI UNO STUDIO COLLABORATIVO APERTO

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this